<unk> , sold under the trade names Olysio among others, is a medication used in combination with other medications for the treatment of hepatitis C. It is specifically used for hepatitis C genotype 1 and 4. Medications it is used with include sofosbuvir or ribavirin and peginterferon-alfa. Cure rates are in 80s to 90s percent. It may be used in those who also have HIV/AIDS. It is taken by mouth once daily for typically 12 weeks. Common side effects include feeling tired, headache, rash, itchiness, and sensitivity to sunlight. In those with previous hepatitis B infection, active disease may recur. It is not recommended in those with significant liver problems. During pregnancy when used with ribavirin it may cause harm to the baby while when used with sofosbuvir its safety is unclear.<unk>  is a HCV protease inhibitor.<unk>  was developed by Medivir AB and Janssen Pharmaceutica. It was approved for medical use in the United States in 2013. It was removed from the World Health Organization's List of Essential Medicines in 2019. It is not available as a generic medication . In the United Kingdom a course of treatment with ribavirin and peginterferon-alfa cost about £29,700 in 2015. In the United States a course of treatment with sofosbuvir was more than 171,000 in 2015 with the<unk>  component costing 66,360.
Simeprevir
Saquinavir
Telaprevir
Fosamprenavir
Glecaprevir
Abacavir
Indinavir
Fostemsavir